From these results, it has been shown that also other genes, such as the estrogen receptor or receptor tyrosine-protein kinase erbB-2 (HER2/neu), play a significant role in the disease, and that it is crucial to properly select the patient group with a known tumor genome to achieve successful treatment outcomes. This evidence concerns the gene ERBB2 and neoplasm.